Search Results 241-250 of 16651 for alopecia

1. Actinic keratosis - Doctors and departments - Mayo Clinic

   Lichen sclerosus, Lichen planus, Skin wrinkles, Vulvar disorder, Acne, Alopecia areata, Melasma, Age spots, UV skin damage, Rosacea, Canker sores, Actinic ...

2. Dermatology - Overview - Mayo Clinic

   They perform Mohs micrographic surgery, laser surgery, cosmetic surgery and other dermatologic surgical procedures. A team focused on you. Many people with skin ...

3. A Phase 1/​2 Study of STP938 for Adult Subjects With Relapsed/​Refractory B-Cell and T-Cell Lymphomas - Mayo Clinic

   - Adequate organ function (bone marrow, hepatic, renal function and coagulation). - All toxicities (except alopecia) from prior cancer treatments or procedures ...

4. Low-Dose or High-Dose Lenalidomide in Treating Children with Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma - Mayo Clinic

   ... alopecia, weight changes and grade I or II lymphopenia. Myelosuppressive chemotherapy: must not have received within 3 weeks of entry onto this study (6 ...

5. Study to Evaluate Chemoembolization Combined with Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma - Mayo Clinic

   Patients with vitiligo or alopecia; ... Any unresolved toxicity National Cancer Institute (NCI) CTCAE v 5.0 Grade ≥ 2 from previous anticancer therapy, with the ...

6. Phase I Study of LB-100 With Docetaxel in Solid Tumors - Mayo Clinic

   Patients must have recovered from all acute adverse effects (excluding alopecia) of prior therapies to baseline or ≤ grade 1 prior to study entry. Patients ...

7. Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 - Mayo Clinic

   Significant autoimmune disease with the exception of alopecia, vitiligo, hypothyroidism or other conditions that have never been clinically active or were ...

8. A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer - Mayo Clinic

   - Toxicities from previous anti-cancer therapies that have not resolved to baseline levels or to Grade 1 or less except for alopecia and peripheral neuropathy.

9. Study of Oral LOXO-338 in Patients With Advanced Blood Cancers - Mayo Clinic

   equal to (≤) 1 or pretreatment baseline, with the exception of alopecia. - Men with partners of childbearing potential or women of childbearing potential ...

10. Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer - Mayo Clinic

    Any unresolved toxicity > Common Toxicity Criteria Grade 1 (except alopecia) from previous anticancer therapy (including radiotherapy); History or evidence ...